Shares of Novartis AG (VTX:NOVN) have been assigned a consensus rating of “Hold” from the twenty research firms that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, nine have given a hold rating and nine have assigned a buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is CHF 91.55.
A number of equities analysts have recently commented on NOVN shares. Deutsche Bank set a CHF 96 target price on shares of Novartis and gave the stock a “neutral” rating in a research report on Monday, December 10th. UBS Group set a CHF 82 price objective on shares of Novartis and gave the company a “neutral” rating in a report on Wednesday, November 21st. Goldman Sachs Group set a CHF 88 price objective on shares of Novartis and gave the company a “neutral” rating in a report on Monday, October 22nd. Kepler Capital Markets set a CHF 94 price objective on shares of Novartis and gave the company a “buy” rating in a report on Monday, December 10th. Finally, Credit Suisse Group set a CHF 86 price objective on shares of Novartis and gave the company a “neutral” rating in a report on Friday, October 19th.
Novartis has a 1 year low of CHF 72.45 and a 1 year high of CHF 88.30.
Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.
Recommended Story: Intrinsic Value and Stock Selection
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.